NCT00452023 2024-12-11
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
48 trialsNCT00002965 2023-12-22
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT01359956 2023-04-11
SICOG 0109
National Cancer Institute, Naples
Phase 3 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT00001113 2021-11-04
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00000687 2021-11-03
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT00000725 2021-11-03
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00000694 2021-11-02
A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00001114 2021-11-01
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT00000764 2021-10-28
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT02174172 2020-05-12
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00038376 2018-10-29
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01943422 2018-04-03
12-107
University of Pittsburgh
Phase 1 Completed
NCT02199327 2017-08-08
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Coordinación de Investigación en Salud, Mexico
Phase 4 Completed
NCT00006244 2017-07-12
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00204529 2017-05-03
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
University Hospital Tuebingen
Phase 3 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT00126594 2016-09-16
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00738530 2016-06-23
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Hoffmann-La Roche
Phase 3 Completed
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00796757 2015-05-27
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Hoffmann-La Roche
Phase 2 Completed
NCT00082719 2015-05-14
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01462773 2015-01-13
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00520403 2014-10-13
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT01609010 2014-09-08
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
Hoffmann-La Roche
Phase 3 Completed
NCT00002621 2014-07-24
Interferon Alfa in Treating Children With HIV-Related Cancer
Children's Oncology Group
Phase 2 Completed
NCT01639885 2014-01-07
CHIP
Leiden University Medical Center
Phase 1/2 Completed
NCT00059813 2013-08-26
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00619268 2013-02-15
TORAVA
Centre Leon Berard
Phase 2 Completed
NCT01404936 2013-02-01
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00416429 2012-09-26
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Phase 3 Completed
NCT00003239 2012-07-30
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00068575 2012-02-15
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00908869 2012-01-30
METRO1
Institut Paoli-Calmettes
Phase 1 Completed
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00083889 2010-01-26
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Pfizer
Phase 3 Completed
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed
NCT00001567 2008-03-04
A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed